Latest Conference Articles

Study results show PCSK9 inhibitor alirocumab reduces cholesterol by increasing the fractional clearance rate of IDL and LDL.

Reducing the risk that stroke patients face of falling can be a matter of chosing proper oral anticoagulants.Researchers said edoxaban is less risky than warfarin.

The scoring system known as CHA2DS2-VASc is commonly used as a clinical guideline for assessing ischemic stroke risk in patients with atrial fibrillation (AF). A research team from Santiago, Chile found it can also predict vascular dysfunction and cardiovascular events in high-risk patients who do not have AF.

Independent of cardiac risk factors, including chronological age and blood pressure preserved telomere length "represents healthy cellular aging," Dhananjay Vaidya and colleagues at Johns Hopkins University reported in an abstract.

The world of medicine is changing and because of that organizations need to change as well. The American College of Allergy, Asthma, & Immunology is no exception to that trend.

It is a changing landscape for everyone in the healthcare field and those who work in allergy and immunology are no exception. How they react to these changes can determine how successful their practices are going forward.

Despite being a well known condition with many treatment options on the market many patients with asthma still struggle to manage their symptoms on a daily basis. New approaches to treatment are working to address these issues and more.

A New York City research team believes that clinical SLE disease is associated with microbiome imbalances, specifically with decreases in the diversity and blooms of specific operational taxonomic units in the intestine.

Patients who had bariatric surgery and lost weight were likely to also see improvement in symptoms of psoriasis and psoriatic arthritis, NYU Langone researchers report.

Estimates on the prevalence of systemic lupus erythematosus (SLE) in the US vary widely. To remedy that situation, the US Centers for Disease Control and Prevention supported four health departments and the Indian Health Service in efforts to get better data.

A Swiss team found that tocilizumab (Actemra/Genentech) was effective in treating newly diagnosed or relapsed patients with giant cell arteritis.

A UK team reporting at the American College of Rheumatology Annual Meeting in San Francisco, CA said it found that adalimumab (Humira/AbbVie) helped patients who had active JIA-associated uveitis

Study results show treatment with tofacitinib imrpveos symptoms in patients with ankylosing spondylitis.

A multinational group known as GRAPPA has compiled a new set of treatment recommendations for psoriasis and psoriatic arthritis.

Giant cell arteritis is effectively treated with glucocorticoids, but they have side effects and patients tend to relapse. Researchers evaluated abatacept combined with prednisone and saw fewer relapses.

A research team in the UK looked at how well rituximab (Rituxan/Genentech) improved the Sjogren's Syndrome symptoms of fatigue and dry mouth.

Even with the combination of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), about 46% of young patients still suffer from poorly controlled asthma. A new analysis found that an add-on inhaler may be just what patients need to reach improved lung function.

Peanut allergies are a common concern in the public, especially in regards to children. While the number of children and adults with this allergy continues to grow the work to help keep them and the people around them safe also has increased in recent years.

While clinicians should always encourage their patients to follow their medication schedules, it proved not to be a significant factor in the outcomes in patients with asthma taking omalizumab, according to a poster session at the 2015 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (ACAAI 2015) in San Antonio, Texas.

Imagine if a study was showing such a mass amount of evidence supporting the safety of an investigational prescription for severe asthma that it had to be stopped early. It may be the best kind of problem to have.

When most people think of vaccines their first thought is often the flu shot. For many patients, especially older patients there are other conditions to consider as well.

While many people get their flu vaccine on a yearly basis there are some who are still hesitant while others simply refuse. New modes of delivery and new guidelines aim to help answer some lingering questions patients may have.

Although gout has historically been thought to be a rare in patients with SLE, a recent case series suggests that the incidence of gout in SLE may be greater than previously thought, University of Michigan researchers report.

With food allergies being a common problem in schools a program is looking at ways to help bring a possible treatment to help keep kids safe from potentially dangerous allergic reactions.

Asthma presents its own set of challenges, as does chronic obstructive pulmonary disease (COPD). When characteristics from both merge together it causes asthma-COPD overlap syndrome (ACOS).

For patients with severe seasonal allergies the regularly available medications may not be enough to help their symptoms while the prospect of shots may be prohibitive enough to keep them from getting shots. A newly approved treatment could provide an alternative to the needle.

Although smartphones are commonly used to check the latest news articles (or sometimes more so Facebook updates), the technology has the power to do some good in the world of asthma and allergies.

With the right maintenance treatment, patients with severe and very severe chronic obstructive pulmonary disease (COPD) can safely be weaned off inhaled corticosteroids (ICS).

Whether it's food or environment-related, there are all different types of allergies. The latest developments in pediatric allergy research highlights peanut allergy, skin prick test measures, and tobacco-induced allergy.

Reporting at the American College of Rheumatology Annual Meeting in San Francisco, a team from Japan reported on a novel humanized monoclonal antibody called E6011, one that targets fractalkine-CX3CR1, with a research goal of stopping the chemokine's accumulation in inflamed tissues in rheumatoid arthritis.